[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100533110":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":25,"locations":33,"responsibleParty":61,"collaborators":63,"id":65,"slug":66,"hasResults":67,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":71,"eligibilityCriteria":72,"healthyVolunteers":67,"sex":73,"minAge":74,"maxAge":75,"enrollmentInfo":76,"targetDuration":20,"studyType":79,"phases":80,"briefSummary":82,"conditions":83,"keywords":86,"overallStatus":36,"whyStopped":20,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":102},{"fullName":5,"class":6},"Chulalongkorn University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Locoregional delivery of B7H3\u002FIL-7Ra CAR T cell in DIPG","EXPERIMENTAL","Patients with DIPG for whom CAR T cells will be delivered into the ventricular system\n\nInterventions:\n\nBiological: Autologous B7H3-specific chimeric antigen receptor (CAR) T cell with additional of IL-7Ra signaling domain Dose level: 1x10e7 CAR T cell, 3x10e7 CAR T cell, 10x10e7 CAR T cell",[13],"Biological: B7H3 specific CAR T cell with IL-7Ra signaling domain",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"BIOLOGICAL","B7H3 specific CAR T cell with IL-7Ra signaling domain","Autologous T cells lentivirally transduced to express a B7H3 specific chimeric antigen receptor (CAR) with additional of IL-7 receptor alpha signalingdomain given via indwelling central nervous system (CNS) catheter",[9],null,[22],{"name":23,"affiliation":5,"role":24},"Piti Techavichit, MD","PRINCIPAL_INVESTIGATOR",[26,30],{"name":23,"role":27,"phone":28,"phoneExt":20,"email":29},"CONTACT","6622564900","piti.t@chula.ac.th",{"name":31,"role":27,"phone":28,"phoneExt":20,"email":32},"Koramit Suppipat, MD","koramit.s@chula.ac.th",[34],{"facility":35,"status":36,"city":37,"state":38,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"King Chulalongkorn Memorial Hospital","RECRUITING","Bangkok","Pathumwan","10330","Thailand","TH",{"type":43,"coordinates":44},"Point",[45,46],100.50144,13.75398,{"lat":46,"lon":45},[49,51,55,56,58,59],{"name":23,"role":27,"phone":50,"phoneExt":20,"email":29},"+66817515363",{"name":52,"role":27,"phone":53,"phoneExt":20,"email":54},"Kanhatai Chiengthong, MD","+66814430961","kanhatai.c@chula.ac.th",{"name":23,"role":24,"phone":20,"phoneExt":20,"email":20},{"name":31,"role":57,"phone":20,"phoneExt":20,"email":20},"SUB_INVESTIGATOR",{"name":52,"role":57,"phone":20,"phoneExt":20,"email":20},{"name":60,"role":57,"phone":20,"phoneExt":20,"email":20},"Supannikar Tawinwung, PhD",{"type":62,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR",[64],{"name":35,"class":6},"100533110","phase-1-safety-and-efficacy-of-loco-regional-b7h3-il-7ra-car-t-cell-in-dipg-100533110",false,"NCT06221553","Safety and Efficacy of Loco-regional B7H3 IL-7Ra CAR T Cell in DIPG","Safety and Efficacy of Intraventricular Infusion of B7H3 With IL-7 Receptor Alpha Signaling Chimeric Antigen Receptor T Cell in Diffuse Intrinsic Pontine Glioma","CMD03DIPG","Inclusion Criteria:\n\n1. Participants must have diffuse intrinsic pontine glioma at any timepoint following completion of standard radiotherapy\n2. Age 1-18 years\n3. Sex: Male or female\n4. CNS reservoir catheter, such as an Ommaya or Rickham catheter, present in the proper location for CNS-directed therapy\n5. Performance status: Lansky or Karnofsky score \\>= 60\n6. Life expectancy \\>= 8 weeks\n7. Normal organ function:\n\n   7.1 AST (SGOT) \\< 5 times the upper limit of normal (ULN) 7.2 ALT (SGPT) \\< 5 times the upper limit of normal (ULN) 7.3 Total bilirubin \\< 3 times the upper limit of normal (ULN) 7.4 Creatinine \\< 5 times the upper limit of normal (ULN) 7.5 SpO2 room air \\>=90%\n8. Prior therapy wash-out before planned leukapheresis 8.1 \\>= 7 days post last chemotherapy\u002Fbiologic therapy administration 8.2 3 half-lives or 30 days, whichever is shorter after the last dose of antitumor antibody therapy 8.3 At least 30 days from most recent cellular infusion 8.4 All systemically administered corticosteroid treatment therapy must be stable or decreasing within 1 week prior to enrollment with a maximum dexamethasone dose of 2.5 mg\u002Fm2\u002Fday. Corticosteroid physiologic replacement therapy is allowed\n9. Participants and\u002For legal guardians must have the ability to understand and willingness to sign a written informed consent and\u002For assent document\n\nExclusion Criteria:\n\n1. Presence of \\>= grade 3 cardiac dysfunction or symptomatic arrythmia requiring intervention\n2. Presence of primary immunodeficiency or bone marrow failure syndrome\n3. Presence of clinical and\u002For radiographic evidence of impending herniation of CNS\n4. Presence of \\> Grade 3 dysphagia\n5. History of active malignancy other than nonmelanoma skin cancer and carcinoma in situ (e.g., cervix, bladder, breast).\n6. Presence of uncontrolled intercurrent illness including but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, pulmonary abnormalities, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements.\n7. Pregnant or breastfeeding women were excluded from this study because CAR-T-cell therapy may be associated with the potential for teratogenic or abortifacient effects. Women of childbearing potential must have a negative serum pregnancy test. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with CAR-T cells, breastfeeding should be discontinued. These potential risks may also apply to other agents used in this study. Participants of childbearing or child-fathering potential must be willing to practice birth control from the time of enrollment in this study and for four months after receiving CAR-T-cell infusion.\n8. Serologic status reflecting active HIV, hepatitis B or C infection. Participants who are positive for hepatitis B core antibody, hepatitis B surface antigen or hepatitis C antibody must have negative PCR prior to enrollment.","ALL","1 Year","18 Years",{"count":77,"type":78},9,"ESTIMATED","INTERVENTIONAL",[81],"PHASE1","A Phase 1 clinical trial to evaluate the safety and early efficacy of CAR T-cell with IL-7Ra signal targeting B7H3 in children with diffuse intrinsic pontine glioma (DIPG) patients after complete standard treatments.",[84,85],"DIPG Brain Tumor","Diffuse Intrinsic Pontine Glioma",[87,88,89,90,91,92],"CAR T cell","DIPG","B7H3","IL-7 receptor alpha","Chimeric antigen receptor T cell","Adoptive cellular therapy","2025-03-27",{"date":95,"type":96},"2025-03-30","ACTUAL",{"date":98,"type":96},"2024-03-01",{"date":100,"type":78},"2026-09-01",{"name":5,"class":6},1]